1-(N1-Cytosinyl)-2,2-diethoxyethan | 23485-29-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(N1-Cytosinyl)-2,2-diethoxyethan
• 英文别名: 1-(2,2-Diethoxyethyl)-cytosin；1-(2,2-diethoxyethyl)cytosine；4-amino-1-(2,2-diethoxy-ethyl)-1H-pyrimidin-2-one；4-Amino-1-(2,2-diethoxyethyl)-1h-pyrimidin-2-one；4-amino-1-(2,2-diethoxyethyl)pyrimidin-2-one
• CAS: 23485-29-2
• 化学式: C₁₀H₁₇N₃O₃
• 分子量: 227.263
• InChiKey: IFXJEJPFSHQXKA-UHFFFAOYSA-N

物化性质

• 熔点：
  232-234 °C
• 沸点：
  349.1±52.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  77.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(N1-Cytosinyl)-2,2-diethoxyethan 在 盐酸 、 水 作用下， 生成
  参考文献：
  名称：

  Sequence-defined vinyl sulfonamide click nucleic acids (VS-CNAs) and their assembly into dynamically responsive materials

  摘要：

  通过巯基-迈克尔点击化学和可溶性聚合物支持，开发了一种可扩展的合成策略，用于创造序列定义的DNA类似物。

  DOI：

  10.1039/d0cc04235h
• 作为产物：
  描述：

  2-溴-1,1-二乙氧基乙烷 在 氨 、 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 1-(N1-Cytosinyl)-2,2-diethoxyethan
  参考文献：
  名称：

  Sequence-defined vinyl sulfonamide click nucleic acids (VS-CNAs) and their assembly into dynamically responsive materials

  摘要：

  通过巯基-迈克尔点击化学和可溶性聚合物支持，开发了一种可扩展的合成策略，用于创造序列定义的DNA类似物。

  DOI：

  10.1039/d0cc04235h

文献信息

• Glycopeptide Antibiotic Derivative
  申请人：Nishitani Yasuhiro

  公开号：US20090286717A1

  公开（公告）日：2009-11-19

  The present invention provides a novel glycopeptide antibiotic derivative. These derivatives are represented by the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R A is —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 wherein X 1 , X 2 and X 3 are single bond; heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR 1 — (R 1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO 2 —, or a linkage thereof; or alkylene or alkenylene optionally substituted and optionally interrupted by one or more of said heteroatom-containing group; Y is —NR 2 CO—, —CONR 2 — (R 2 is hydrogen or lower alkyl), or a group of the formula (II) wherein R 3 is alkylene; Ar 1 and Ar 2 are a carbocycle or a heterocycle which is optionally substituted and may have an unsaturated bond; R B is —NHNR X R Y or —NR Z OR W wherein R X is hydrogen or lower alkyl; R Y is hydrogen, optionally substituted lower alkyl, C(═NH)NH 2 , CSNH 2 , COCONH 2 , CN, optionally substituted heterocyclic group, and optionally substituted carbamoyl; R Z is hydrogen or lower alkyl; R W is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted heterocyclic group, optionally substituted heterocyclic carbonyl or optionally substituted carbamoyl; R C is hydrogen or optionally substituted alkyl, wherein said alkyl may be interrupted by a heteroatom-containing group selected from N═, ═N—, —NR 1 — (R 1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO 2 —; and R is optionally substituted alkyl.

  本发明提供了一种新型的糖肽抗生素衍生物。这些衍生物由以下式（I）或其药学上可接受的盐或溶剂表示，其中RA为—X1—Ar1—X2—Y—X3—Ar2，其中X1、X2和X3为单键；从—N═、═N—、—NR1—（R1为氢或较低的烷基）、—O—、—S—、—SO—和—SO2—中选择的含有杂原子的基团，或者它们的连接；或者由一个或多个上述含有杂原子的基团选择性取代和选择性中断的烷基或烯基；Y为—NR2CO—、—CONR2—（R2为氢或较低的烷基），或者具有以下式（II）的基团，其中R3为烷基；Ar1和Ar2为可能取代且可能具有不饱和键的碳环或杂环；RB为—NHNRXRY或—NRZORW，其中RX为氢或较低的烷基；RY为氢、选择性取代的较低烷基、C(═NH)NH2、CSNH2、COCONH2、CN、选择性取代的杂环基团和选择性取代的氨基甲酰；RZ为氢或较低的烷基；RW为氢、选择性取代的较低烷基、选择性取代的较低烯基、选择性取代的杂环基团、选择性取代的杂环酰基或选择性取代的氨基甲酰；RC为氢或选择性取代的烷基，其中所述的烷基可以被从—N═、═N—、—NR1—（R1为氢或较低的烷基）、—O—、—S—、—SO—和—SO2—中选择的含有杂原子的基团中断；且R为选择性取代的烷基。
• Synthesis of Novel Mimetics of CMP-Sialic Acid as the Inhibitors of Sialyltransferases
  作者：Tetsuya Kajimoto、Toru Tanaka、Machiko Ozawa、Tsuyoshi Miura、Toshiyuki Inazu、Shuichi Tsuji

  DOI：10.1055/s-2002-33518

  日期：——

  Novel mimetics of CMP-sialic acid were designed as the inhibitors of sialyltransferases. They were synthesized in a short step from a cytosine carrying β-hydroxy-α-l-amino acid based on the knowledge that nikkomycin, a peptidic derivative of an uracil carrying amino acid, shows a potent inhibitory activity toward N-acetyl-d-glucosaminyltransferases that employ UDP-N-acetyl-d-glucosamine as the donor substrate. The cytosine carrying β-hydroxyl-α-l-amino acid, a key intermediate in our synthetic strategy, was easily prepared by the l-threonine aldolase (LTA) catalyzed reaction.

  我们设计了 CMP-硅酸的新型模拟物作为硅氨酰转移酶的抑制剂。根据携带尿嘧啶的氨基酸的肽衍生物尼可霉素对使用 UDP-N- 乙酰基-d-葡糖胺作为供体底物的 N-乙酰基-d-葡糖胺转移酶具有强效抑制活性的知识，我们在短时间内从携带δ-羟基-±-l-氨基酸的胞嘧啶中合成了它们。在我们的合成策略中，胞嘧啶携带的δ-羟基-δ-±-l-氨基酸是一个关键的中间体，很容易通过 l-苏氨酸醛缩酶（LTA）催化反应制备出来。
• DNA Analysis by Dynamic Chemistry
  作者：Frank R. Bowler、Juan J. Diaz-Mochon、Michael D. Swift、Mark Bradley

  DOI：10.1002/anie.200905699

  日期：2010.3.1

  Finding flaws: An enzyme‐free method of DNA analysis raises the possibility of analyzing single‐nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. The methodology is suitable for the dual analysis of heterozygous samples.

  发现缺陷：DNA的无酶分析方法提高了使用质谱法作为读出工具分析单核苷酸多态性，插入缺失和无碱基位点的可能性。该方法适用于杂合样品的双重分析。
• Templated Synthesis of Peptide Nucleic Acids via Sequence-Selective Base-Filling Reactions
  作者：Jennifer M. Heemstra、David R. Liu

  DOI：10.1021/ja904712t

  日期：2009.8.19

  The templated synthesis of nucleic acids has previously been achieved through the backbone ligation of preformed nucleotide monomers or oligomers. In contrast, here we demonstrate templated nucleic acid synthesis using a base-filling approach in which individual bases are added to abasic sites of a peptide nucleic acid (PNA). Because nucleobase substrates in this approach are not self-reactive, a base-filling

  核酸的模板化合成以前是通过预先形成的核苷酸单体或寡聚体的骨架连接来实现的。相比之下，我们在这里展示了使用碱基填充方法的模板化核酸合成，其中将单个碱基添加到肽核酸 (PNA) 的无碱基位点。由于这种方法中的核碱基底物不具有自反应性，因此碱基填充方法可能会减少非模板化反应产物的形成。使用还原胺化或胺酰化化学，我们观察到四种核碱基中的每一种都有效且选择性地添加到 PNA 链中间的无碱基位点。我们还描述了通过碱基填充将单个核碱基添加到 PNA 链的末端，以及将两个碱基串联添加到 PNA 链的中间。
• Glycopeptide antibiotic derivative
  申请人：Nishitani Yasuhiro

  公开号：US08933012B2

  公开（公告）日：2015-01-13

  The present invention provides a novel glycopeptide antibiotic derivative. These derivatives are represented by the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein RA is —X1—Ar1—X2—Y—X3—Ar2 wherein X1, X2 and X3 are single bond; heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR1— (R1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO2—, or a linkage thereof; or alkylene or alkenylene optionally substituted and optionally interrupted by one or more of said heteroatom-containing group; Y is —NR2CO—, —CONR2— (R2 is hydrogen or lower alkyl), or a group of the formula (II) wherein R3 is alkylene; Ar1 and Ar2 are a carbocycle or a heterocycle which is optionally substituted and may have an unsaturated bond; RB is —NHNRXRY or —NRZORW wherein RX is hydrogen or lower alkyl; RY is hydrogen, optionally substituted lower alkyl, C(═NH)NH2, CSNH2, COCONH2, CN, optionally substituted heterocyclic group, and optionally substituted carbamoyl; RZ is hydrogen or lower alkyl; RW is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted heterocyclic group, optionally substituted heterocyclic carbonyl or optionally substituted carbamoyl; RC is hydrogen or optionally substituted alkyl, wherein said alkyl may be interrupted by a heteroatom-containing group selected from N═, ═N—, —NR1— (R1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO2—; and R is optionally substituted alkyl.

  本发明提供了一种新型的糖肽类抗生素衍生物。这些衍生物由式(I)或其药学上可接受的盐或溶剂表示，其中RA为-X1-Ar1-X2-Y-X3-Ar2，其中X1、X2和X3为单键；异原子含有的基团，所选的基团来自于-N═，═N—，—NR1—（R1为氢或低碳基），—O—，—S—，—SO—和—SO2—，或它们之间的连接；或者是烷基或烯基，可选择地被一个或多个上述异原子含有的基团取代和中断；Y为-NR2CO—，—CONR2—（R2为氢或低碳基），或式(II)的基团，其中R3为烷基；Ar1和Ar2为可选择地取代和可能具有不饱和键的碳环或杂环；RB为-NHNRXRY或-NRZORW，其中RX为氢或低碳基；RY为氢，可选择地取代的低碳基，C(═NH)NH2，CSNH2，COCONH2，CN，可选择地取代的杂环基团和可选择地取代的氨基甲酰基；RZ为氢或低碳基；RW为氢，可选择地取代的低碳基，可选择地取代的低碳烯基，可选择地取代的杂环基团，可选择地取代的杂环羰基或可选择地取代的氨基甲酰基；RC为氢或可选择地取代的烷基，其中所述的烷基可能被一个异原子含有的基团所中断，所选的基团来自于N═，═N—，—NR1—（R1为氢或低碳基），—O—，—S—，—SO—和—SO2—；R为可选择地取代的烷基。